Koziolek M, Beige J, Wallbach M, Zenker D, Henning G, Halbach M, Mader N, Mahfoud F, Schlieper G, Schwenger V, Hausberg M, Börgel J, Lodde M, van der Giet M, Müller-Ehmsen J, Passauer J, Parmentier S, Lüders S, Krämer B K, Büttner S, Limbourg F, Jordan J, Vonend O, Predel H-G, Reuter H
Klinik für Nephrologie und Rheumatologie, Universitätsmedizin Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Deutschland.
Abteilung Nephrologie und KfH-Nierenzentrum, Klinikum St. Georg Leipzig, Leipzig, Deutschland.
Internist (Berl). 2017 Oct;58(10):1114-1123. doi: 10.1007/s00108-017-0308-y.
Baroreceptor activation therapy (BAT) has been available for several years for treatment of therapy-refractory hypertension (trHTN). This procedure is currently being carried out in a limited number of centers in Germany, also with the aim of offering a high level of expertise through sufficient experience; however, a growing number of patients who are treated with BAT experience problems that treating physicians are confronted with in routine medical practice. In order to address these problems, a consensus conference was held with experts in the field of trHTN in November 2016, which summarizes the current evidence and experience as well as the problem areas in handling BAT patients.
压力感受器激活疗法（BAT）已应用于治疗难治性高血压（trHTN）数年。目前，德国仅有少数几个中心开展该治疗，目的也是通过积累足够的经验提供高水平的专业治疗；然而，越来越多接受BAT治疗的患者出现了一些问题，这些问题是治疗医生在日常医疗实践中所面临的。为了解决这些问题，2016年11月与trHTN领域的专家召开了一次共识会议，会议总结了当前的证据和经验以及在处理BAT患者时存在问题的领域。
